The DOI matches its Crossref record.
Tamoxifen for early breast cancer: an overview of the randomised trials
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
No references could be resolved yet.
Research works printed but not linked: 22
- 1988, Effects of adjuvant tamoxifen and of cytotoxic therapy on mortality in early breast cancer: an overview of 61 randomised trials among 28,896 women, N Engl J Med, 319, 1681, 10.1056/NEJM198812293192601 · DOI · Paper page
- 1992, Systemic treatment of early breast cancer by hormonal, cytotoxic, or immune therapy: 133 randomised trials involving 31 000 recurrences and 24 000 deaths among 75 000 women, Lancet, 339, 1
- 1995, Effects of radiotherapy and surgery in early breast cancer: an overview of the randomised trials, N Engl J Med, 333, 1444, 10.1056/NEJM199511303332202 · DOI · Paper page
- 1996, Ovarian ablation in early breast cancer: overview of the randomised trials, Lancet, 348, 1189, 10.1016/S0140-6736(96)05023-4 · DOI · Paper page
- Knight, 1980, Hormonal receptors in primary and advanced breast cancer, Clin Endocrinol Metab, 9, 361, 10.1016/S0300-595X(80)80038-7 · doi:10.1016/s0300-595x(80)80038-7
- Elwood, 1980, Oestrogen receptors in breast tumours: associations with age, menopausal status and epidemiological and clinical features in 735 patients, Br J Cancer, 42, 635, 10.1038/bjc.1980.296 · doi:10.1038/bjc.1980.296
- Rutqvist, 1995, Adjuvant tamoxifen therapy for early stage breast cancer and second primary malignancies, J Natl Cancer Inst, 87, 645, 10.1093/jnci/87.9.645 · DOI · Paper page
- 1996, IARC monograph on the evaluation of carcinogenic risks to humans, Some pharmaceutical drugs, 66, 253
- Rutqvist, 1989, Radiotherapy, chemotherapy, and tamoxifen as adjuncts to surgery in early breast cancer: a summary of three randomized trials, Int J Radiation Oncol Biol Phys, 16, 629, 10.1016/0360-3016(89)90478-1 · DOI
- McDonald, 1995, Cardiac and vascular morbidity in women receiving adjuvant tamoxifen for breast cancer in a randomised trial, BMJ, 311, 977, 10.1136/bmj.311.7011.977 · DOI · Paper page
- Fisher, 1994, Endometrial cancer in tamoxifen treated breast cancer patients: findings from the National Surgical Adjuvant Breast and Bowel Project (NSABP) B-14, J Natl Cancer Inst, 86, 527, 10.1093/jnci/86.7.527 · DOI · Paper page
- Williams, 1993, The triphenylethylene drug tamoxifen is a strong liver carcinogen in the rat, Carcinogenesis, 14, 315, 10.1093/carcin/14.2.315 · doi:10.1093/carcin/14.2.315
- Clark, 1997, Estrogen receptor status determined by immuno-histochemistry is superior to biochemical ligand-binding assay for evaluating breast cancer patients, Proc ASCO, 16, 454
- 1996, Randomized trial of two versus five years of adjuvant tamoxifen for postmenopausal early stage breast cancer, J Natl Cancer Inst, 88, 1543, 10.1093/jnci/88.21.1543 · DOI · Paper page
- 1996, Preliminary results from the Cancer Research Campaign Trial evaluating tamoxifen duration in women aged fifty years or older with breast cancer, J Natl Cancer Inst, 88, 1834, 10.1093/jnci/88.24.1834 · DOI
- Delozier, 1997, Short-term versus lifelong adjuvant tamoxifen in early breast cancer (EBC): a randomized trial (TAM-01), Proc ASCO, 16, 1289
- Peto, 1996, Five years of tamoxifen—or more?, J Natl Cancer Inst, 88, 1791, 10.1093/jnci/88.24.1791 · DOI
- Fisher, 1996, The worth of five versus more than five years of tamoxifen therapy for breast cancer patients with negative lymph nodes and estrogen receptor-positive tumors, J Natl Cancer Inst, 88, 1529, 10.1093/jnci/88.21.1529 · DOI · Paper page
- Stewart, 1996, Randomised comparison of 5 years of adjuvant tamoxifen with continuous therapy for operable breast cancer: the Scottish Cancer Trials Breast Group, Br J Cancer, 74, 297, 10.1038/bjc.1996.356 · DOI
- Tormey, 1996, (for the Eastern Cooperative Oncology Group). Postchemotherapy adjuvant tamoxifen therapy beyond five years in patients with lymph node-positive breast cancer, J Natl Cancer Inst, 88, 1828, 10.1093/jnci/88.24.1828 · DOI
- Love, 1991, Effects of tamoxifen on cardiovascular risk factors in postmenopausal women, Ann Intern Med, 115, 860, 10.7326/0003-4819-115-11-860 · DOI · Paper page
- Gotto, 1997, Results of recent large cholesterol-lowering trials and implications for clinical management, Am J Cardiol, 79, 1663, 10.1016/S0002-9149(97)00218-X · DOI
Cited by
Measuring inconsistency in meta-analyses
Higgins, J. P. T., Thompson, S. G., Deeks, J. J., & Altman, D. G. (2003) · BMJ · doi:10.1136/bmj.327.7414.557 · Cited by 63,139
Gene expression profiling predicts clinical outcome of breast cancer
van 't Veer, L. J., Dai, H., van de Vijver, M. J., He, Y. D., Hart, A. A. M., Mao, M., Peterse, H. L., van der Kooy, K., Marton, M. J., Witteveen, A. T., et al. (2002) · Nature · doi:10.1038/415530a · Cited by 9,536
Estrogen receptors: how do they signal and what are their targets
Heldring, N., Pike, A., Andersson, S., Matthews, J., Cheng, G., Hartman, J., Tujague, M., Ström, A., Treuter, E., Warner, M., et al. (2007) · Physiological Reviews · doi:10.1152/physrev.00026.2006 · Cited by 1,857
Goss, P. E., Ingle, J. N., Martino, S., Robert, N. J., Muss, H. B., Piccart, M. J., Castiglione, M., Tu, D., Shepherd, L. E., Pritchard, K. I., et al. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa032312 · Cited by 1,795
Coombes, R. C., Hall, E., Gibson, L. J., Paridaens, R., Jassem, J., Delozier, T., Jones, S. E., Alvarez, I., Bertelli, G., Ortmann, O., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa040331 · Cited by 1,759
Metadata
- Venue
- The Lancet
- Publisher
- Elsevier BV
- Published
- 1998-05
- Volume
- 351
- Issue
- 9114
- Pages
- 1451-1467
- ISSN
- 0099-5355 (ISSN-L)
- 0140-6736
- OpenAlex
- W1562190372
- Cited by
- 4,085
- References
- 0
- FWCI
- 86.27
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.elsevier.com/tdm/userlicense/1.0/ (tdm)
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Tamoxifen for early breast cancer: an overview of the randomised trials. https://app.cochat.ai/papers/10.1016/s0140-6736(97)11423-4
- The paper
- Tamoxifen for early breast cancer: an overview of the randomised trials. (1998). The Lancet. https://doi.org/10.1016/s0140-6736(97)11423-4
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.
